Related Experiment Video
Updated: May 11, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by
Ingrid Cifola1, Alessandro Pietrelli, Clarissa Consolandi
1Institute for Biomedical Technologies, National Research Council, Milan, Italy. ingrid.cifola@itb.cnr.it
Abstract:
Cutaneous malignant melanoma is the most fatal skin cancer and although improved comprehension of its pathogenic pathways allowed to realize some effective molecular targeted therapies, novel targets and drugs are still needed. Aiming to add genetic information potentially useful for novel targets discovery, we performed an extensive genomic characterization by whole-exome sequencing and SNP array profiling of six cutaneous melanoma cell lines derived from metastatic patients. We obtained a total of 3,325 novel coding single nucleotide variants, including 2,172 non-synonymous variants. We catalogued the coding mutations according to Sanger COSMIC database and to a manually curated list including genes involved in melanoma pathways identified by mining recent literature. Besides confirming the presence of known melanoma driver mutations (BRAF(V600E), NRAS(Q61R) ), we identified novel mutated genes involved in signalling pathways crucial for melanoma pathogenesis and already addressed by current targeted therapies (such as MAPK and glutamate pathways). We also identified mutations in four genes (MUC19, PAICS, RBMXL1, KIF23) never reported in melanoma, which might deserve further investigations. All data are available to the entire research community in our Melanoma Exome Database (at https://155.253.6.64/MExDB/). In summary, these cell lines are valuable biological tools to improve the genetic comprehension of this complex cancer disease and to study functional relevance of individual mutational events, and these findings could provide insights potentially useful for identification of novel therapeutic targets for cutaneous malignant melanoma.
Insights
Researchers characterized the genomics of six cutaneous melanoma cell lines, identifying novel mutations and potential therapeutic targets. This genetic data aids in understanding melanoma pathogenesis and developing new treatments for this fatal skin cancer.
Area of Science:
- Oncology
- Genomics
- Dermatology
Background:
- Cutaneous malignant melanoma is a fatal skin cancer.
- Existing molecular therapies improve outcomes, but novel targets are crucial.
- Understanding melanoma's genetic landscape is key to discovering new treatments.
Purpose of the Study:
- To perform extensive genomic characterization of cutaneous melanoma cell lines.
- To identify novel genetic variants and mutations for therapeutic target discovery.
- To provide valuable genetic data for melanoma research.
Main Methods:
- Whole-exome sequencing and SNP array profiling of six metastatic melanoma cell lines.
- Cataloging coding mutations against the COSMIC database and curated gene lists.
- Mining literature for genes involved in melanoma pathogenesis.
Main Results:
- Identified 3,325 novel coding single nucleotide variants, including 2,172 non-synonymous variants.
- Confirmed known driver mutations (BRAF, NRAS) and identified novel mutations in MAPK and glutamate pathways.
- Discovered mutations in four previously unreported melanoma genes: MUC19, PAICS, RBMXL1, and KIF23.
Conclusions:
- The characterized cell lines are valuable tools for understanding melanoma genetics.
- Findings offer insights into melanoma pathogenesis and potential novel therapeutic targets.
- The Melanoma Exome Database provides open access to comprehensive genomic data.
